Related by context. All words. (Click for frequent words.) 74 estrogen receptor progesterone receptor 73 progesterone receptor negative 72 HER2 + 71 HER2 positive 70 HER2 positive metastatic breast 69 hormone receptor positive 69 estrogen receptor negative 69 operable breast cancer 69 mRCC 68 hormone receptor negative 68 estrogen receptor positive 68 neoadjuvant chemotherapy 67 estrogen receptor ER 67 HER2 positive cancers 67 Adjuvant chemotherapy 67 HER2 positive tumors 66 unresectable 66 fallopian tube carcinoma 66 ErbB2 positive 66 KRAS mutations 66 nonmetastatic 66 recurrent NSCLC 66 distant metastases 66 preoperative chemotherapy 66 prostate carcinoma 65 invasive lobular carcinoma 65 Bezielle 65 pancreatic adenocarcinoma 65 EBRT 65 resectable 65 castrate resistant 65 advanced adenomas 65 lymph node involvement 65 adjuvant radiotherapy 65 distant metastasis 65 recurrent metastatic 65 cisplatin resistant 65 locoregional recurrence 65 PSADT 64 epithelial ovarian 64 progesterone receptor PR 64 pCR 64 BRCA deficient 64 chlorambucil 64 stage IIIb IV 64 adjuvant chemotherapy 64 LHRH receptor positive 64 adjuvant therapy 64 contralateral breast 64 metastatic gastric 64 metastatic renal cell carcinoma 64 advanced unresectable 64 invasive carcinoma 64 stage IIIB 64 gemcitabine carboplatin 64 neoadjuvant therapy 64 biochemical recurrence 64 breast carcinoma 64 epithelial tumors 64 adjuvant radiation 64 metastatic HER2 negative 64 metastatic RCC 64 castration resistant prostate cancer 64 K ras mutations 63 whose tumors overexpress 63 EGFR mutation positive 63 ovarian carcinoma 63 underwent surgical resection 63 lymph node metastases 63 metastatic GIST 63 HER2 expression 63 Flu Cy 63 KRAS wild 63 invasive ductal 63 BRCA1 mutation carriers 63 CR nPR 63 locoregional 63 tumor histology 63 gefitinib 63 epithelial ovarian cancer 63 HRPC 63 taxane therapy 63 neoadjuvant 63 completely resected 63 micrometastases 63 anti EGFR antibody 63 oral clodronate 63 metastatic carcinoma 63 metastatic colorectal 63 breast carcinomas 63 mutated K ras 62 PCa 62 relapsed ovarian cancer 62 chemoradiotherapy 62 atypical hyperplasia 62 recurrent glioblastoma multiforme 62 HER-2/neu 62 HGPIN 62 histologically confirmed 62 alkylating agents 62 metastatic breast cancer 62 Hurthle cell 62 mycophenolate mofetil 62 adriamycin 62 postoperative chemotherapy 62 endometrial cancers 62 unresectable locally advanced 62 pT2 62 metastatic disease 62 hepatocellular carcinomas 62 FOLFOX4 62 goserelin 62 metastatic bladder 62 situ LCIS 62 plus dexamethasone 62 differentiated thyroid 62 metastatic colorectal cancer 62 axillary nodes 62 antiangiogenic therapy 62 pT3 62 cisplatin chemotherapy 62 medically inoperable 62 recurrent ovarian cancer 62 small lymphocytic lymphoma 62 lymphocytosis 62 lobular carcinomas 62 epirubicin 62 refractory NSCLC 62 chemoradiation 62 gemcitabine chemotherapy 61 androgen deprivation 61 overexpress HER2 61 xenograft models 61 hepatocellular cancer 61 ERBB2 61 HER2 61 hormone refractory 61 HER2 amplified 61 HER2 receptor 61 tamoxifen therapy 61 endocrine therapy 61 T1c 61 assessing T DM1 61 clinically localized prostate 61 androgen independent 61 metastatic pancreatic 61 refractory multiple myeloma 61 cervical carcinoma 61 SLNB 61 carboplatin paclitaxel 61 castrate resistant prostate cancer 61 relapsed SCLC 61 nonsmall cell lung cancer 61 NSCLC 61 liver metastases 61 papillary thyroid carcinoma 61 pegylated liposomal doxorubicin 61 KRAS mutant tumors 61 previously untreated follicular 61 trastuzumab 61 TNF antagonist 61 grade cervical intraepithelial 61 cisplatin vinorelbine 61 Doxil ® 61 cystectomy 61 docetaxel 61 paclitaxel cisplatin 61 CIN3 61 tumor recurrence 61 ASCUS 61 KRAS status 61 KRAS mutations occur 61 axillary lymph nodes 61 docetaxel chemotherapy 61 Castration Resistant Prostate Cancer 61 HER2 positive breast 61 coinfected 61 biliary tract cancer 61 progesterone receptors 61 colorectal liver metastases 61 recurrent ovarian 61 taxane chemotherapy 61 mutated KRAS 61 Hodgkin lymphoma HL 61 adjuvant tamoxifen 61 Folfox 61 superficial bladder cancer 61 anthracycline taxane 60 Platinol 60 iniparib 60 histologies 60 heavily pretreated 60 CRu 60 CCyR 60 antiandrogen 60 HCV genotype 60 skeletal metastases 60 FOLFOX 60 histologic subtype 60 tumors GIST 60 progesterone receptor 60 brain metastases 60 ovarian endometrial 60 HER2 amplification 60 FOLFOX6 60 gefitinib Iressa 60 paclitaxel carboplatin 60 #.#ng/ml 60 hormonal therapy 60 XELOX 60 cytoreduction 60 metastatic renal cell 60 CIN2 + 60 pancreatic neuroendocrine tumors 60 prostate cancer CRPC 60 hepatocellular carcinoma HCC 60 mutated KRAS gene 60 BCG refractory 60 median PFS 60 lobular carcinoma 60 anastrazole 60 mCRC patients 60 clodronate 60 Fludara 60 eribulin 60 ALND 60 EGFR mutation 60 dacarbazine DTIC 60 hormone refractory prostate cancer 60 hepatic metastases 60 B CLL 60 axillary dissection 60 Erlotinib 60 urothelial carcinoma 60 BRAF V#E mutation 60 prostate cancer CaP 60 castration resistant 60 lymph node metastasis 60 moderate renal impairment 60 demonstrated antitumor activity 60 advanced hepatocellular carcinoma 60 squamous histology 60 nonresponders 60 non mutated KRAS 60 NMIBC 60 temsirolimus 60 invasive lobular 60 situ CIS 60 EGFR mutations 60 IV NSCLC 60 pancreatic lung 60 TTF Therapy 60 Peginterferon alfa 2b 60 biochemical relapse 60 poorer prognosis 60 cervical intraepithelial neoplasia 60 splenectomized patients 60 GnRH agonists 60 chemotherapy docetaxel 60 haematologic 60 metastatic prostate cancer 60 anthracycline containing 60 untreated metastatic melanoma 60 minimally symptomatic 60 malignant pleural mesothelioma 60 infliximab monotherapy 60 5-FU/LV 60 medullary thyroid cancer 60 stage IIIB IV 60 luteinizing hormone releasing 60 BRCA mutation carriers 60 neoadjuvant treatment 60 evaluating T DM1 60 colorectal carcinoma 60 Fludara ® 60 HNSCC 60 TACE 60 refractory AML 60 seminoma 60 breast cancer subtypes 60 Recurrence Score 60 EndoTAGTM 1 60 unresectable stage 60 poly ADP ribose polymerase 60 endocrine therapies 60 Hepatocellular Carcinoma HCC 59 pulmonary metastases 59 atypia 59 dacarbazine 59 trastuzumab Herceptin R 59 HGS ETR2 59 Herceptin trastuzumab 59 relapsed MM 59 ductal breast cancer 59 colon carcinoma 59 Amrubicin 59 gemcitabine Gemzar 59 lymphadenectomy 59 sarcomatoid 59 curative resection 59 metastatic colorectal carcinoma 59 DLBCL 59 cabazitaxel 59 follicular NHL 59 MAGE A3 59 ductal carcinomas 59 fallopian tube cancers 59 FOLFIRI alone 59 T#I [002] 59 lymphovascular invasion 59 metastatic malignant 59 FOLFIRI 59 5FU 59 extracapsular extension 59 urothelial bladder cancer 59 CYT# potent vascular disrupting 59 chemoembolization 59 Gleevec resistant 59 adjuvant cisplatin 59 resected 59 metastatic hormone refractory 59 MAGE A3 ASCI 59 CIN2 59 LHRH agonists 59 HGS ETR1 59 temozolomide TMZ 59 Squamous 59 trabectedin 59 Lenalidomide 59 bone metastasis 59 baseline LDH 59 HBeAg negative 59 stage IIIA 59 fluoropyrimidine 59 chemoresistant 59 adjuvant therapies 59 metastatic 59 prior chemotherapy regimens 59 non squamous histology 59 node metastases 59 achieved ACR# 59 gemcitabine 59 flutamide 59 endometrial carcinoma 59 histological subtype 59 vinorelbine 59 alvespimycin 59 cisplatin 59 serous ovarian cancer 59 heavily pretreated patients 59 invasive carcinomas 59 HER2 ErbB2 59 papillary renal cell carcinoma 59 mucinous 59 metastatic HRPC 59 sorafenib Nexavar 59 resistant hormone refractory 59 leukemia APL 59 gastrointestinal stromal tumors 59 BRAF mutation 59 Her2 59 neoplasia 59 interferon alfa 2b 59 letrozole 59 5-fluorouracil/leucovorin 59 TT genotype 59 EGFR expressing 59 cetuximab 59 tamoxifen Nolvadex ® 59 gastric adenocarcinoma 59 vandetanib 59 oblimersen 59 estramustine 59 chemotherapy cisplatin 59 immunohistochemical staining 59 Tesmilifene 59 Temsirolimus 59 EGFR TKI 59 HER2 overexpression 59 micrometastasis 59 peritoneal carcinomatosis 59 Her2/neu 59 baseline neutrophil counts 59 thyroglobulin 59 HCV SPRINT 59 carcinomas 59 Vectibix 59 Thal Dex 59 alfa 2a 59 Stage IIIb 59 advanced adenoma 59 Kaplan Meier analysis 59 refractory colorectal cancer 59 Fludarabine 58 underwent resection 58 contralateral breast cancer 58 trans retinoic acid ATRA 58 metastatic CRPC 58 leukemia AML 58 TNF blocker therapy 58 metastatic HER 58 leukemia CLL 58 partial remissions 58 MGd 58 PSA nadir 58 Papillary 58 postoperative radiotherapy 58 radiation chemoradiation 58 dasatinib Sprycel 58 RECIST Response Evaluation Criteria 58 Telintra 58 Irinotecan 58 imatinib Gleevec 58 bladder carcinoma 58 VELCADE melphalan 58 cytotoxic therapy 58 sorafenib tablets 58 non resectable 58 neoplasias 58 prognostic factor 58 intravesical therapy 58 advanced NSCLC 58 invasive ductal carcinoma 58 HGS ETR1 mapatumumab 58 ACTEMRA TM 58 Response Evaluation Criteria 58 virologic failure 58 prostate cancer AIPC 58 metastatic kidney 58 gastrointestinal stromal tumor GIST 58 carboplatin 58 platinum refractory 58 T1a 58 #mg dose [002] 58 dasatinib 58 FOLPI 58 TOP2A 58 dasatinib Sprycel ® 58 squamous cell carcinoma SCC 58 hormone receptor status 58 ribavirin therapy 58 Her2 positive 58 ovarian lung 58 low dose cytarabine 58 KRAS mutant 58 pheochromocytomas 58 progression TTP 58 adenocarcinomas 58 EGFR inhibitors 58 pegylated interferon alfa 2a 58 chemoradiation therapy 58 standard chemotherapy regimen 58 metastatic breast 58 alkylating agent 58 YONDELIS 58 unresectable tumors 58 Multiple Myeloma MM 58 metastatic castration resistant 58 syngeneic 58 renal tumors 58 thyroid carcinoma 58 histologic subtypes 58 intestinal metaplasia 58 complete cytogenetic response 58 mitoxantrone 58 BRCA mutation 58 endometrial hyperplasia 58 daunorubicin 58 erlotinib Tarceva ® 58 refractory indolent non 58 GISTs 58 IV bisphosphonates 58 cancer mCRC 58 non squamous 58 receptor tyrosine kinase inhibitor 58 endometrioid 58 BRCA mutations 58 glufosfamide 58 antiandrogens 58 metaglidasen 58 papillary 58 galiximab 58 metastatic renal 58 ZACTIMA 58 standard chemotherapy regimens 58 Neoadjuvant 58 acute myelogenous leukemia AML 58 non metastatic osteosarcoma 58 EGFR expressing mCRC 58 Ixempra 58 hormone deprivation 58 CaP 58 Platinol ® cisplatin 58 pertuzumab 58 lung metastases 58 cyclophosphamide methotrexate 58 non squamous NSCLC 58 amrubicin 58 SPINK1 58 basal cell carcinoma BCC 58 efaproxiral 58 lymphomas leukemias 58 elevated LDH 58 evaluating tivozanib 58 IV melanoma 58 pediatric malignancies 58 Paraplatin ® 58 adjuvant hormonal therapy 58 carcinoembryonic antigen CEA 58 bendamustine 58 fludarabine 58 prostate adenocarcinoma 58 breast pancreatic 58 sentinel lymph node biopsy 58 docetaxel Taxotere ® 58 coinfected patients 58 nilotinib 58 metastatic malignant melanoma 58 debulking surgery 58 Metastatic 58 Insegia 58 lung pancreatic 58 prostate cancer HRPC 58 advanced epithelial ovarian 58 Zolinza 58 plus dacarbazine 58 EpCAM 58 advanced metastatic renal 58 EFAPROXYN 58 mitoxantrone chemotherapy 58 CRp 58 CR CRu 58 malignant pleural mesothelioma MPM 58 CHOP chemotherapy 58 advanced HER2 positive 58 multiple myeloma MM 58 bladder cancers 58 pomalidomide 58 iniparib BSI 58 pancreatic carcinoma 58 metastatic pancreatic cancer 58 BRCA2 carriers 58 liver metastasis 58 Capecitabine 58 6 mercaptopurine 58 achieved CCyR 58 hematopoietic cancers 58 breast tumors 58 prostate cancer PCa 58 undetectable HBV DNA 58 ZOLINZA 58 hypermethylated 58 fulvestrant 58 myelodysplastic myeloproliferative diseases 58 Genasense ® 58 sorafenib Nexavar ® 58 antimetabolite 58 dexamethasone Decadron 58 pamidronate 58 irinotecan chemotherapy 58 radiotherapy RT 58 GnRH agonist 58 Azacitidine 57 ovarian breast 57 EUS FNA 57 systemic ALCL 57 placebo dexamethasone 57 renal cell carcinomas 57 olaparib 57 adenoma recurrence 57 anastrozole 57 atypical ductal hyperplasia 57 concurrent chemoradiation 57 peritoneal cancer 57 Gliadel Wafer 57 SCCHN 57 panobinostat 57 glioblastoma multiforme GBM 57 doublet chemotherapy 57 LNG IUS 57 receptor blocker 57 evaluable 57 lenalidomide Revlimid R 57 dutasteride 57 bortezomib 57 nodal metastasis 57 chronic lymphocytic leukemia CLL 57 ixabepilone 57 prognostic indicator 57 AVODART 57 tibolone 57 receiving highly emetogenic 57 histologically proven 57 histologically 57 normal karyotype 57 seminal vesicle invasion 57 trastuzumab DM1 57 castration resistant hormone refractory 57 p#HER# 57 CLL SLL 57 imatinib therapy 57 FLT3 57 recurrent GBM 57 FDG uptake 57 renal carcinoma 57 Taxotere chemotherapy 57 colorectal carcinomas 57 interferon ribavirin 57 follicular lymphomas 57 metastatic NSCLC 57 radiochemotherapy 57 cytogenetic response 57 System IPSS 57 Peg IFN 57 mg kg dose 57 colorectal neoplasms 57 ALIMTA cisplatin 57 melphalan prednisone 57 neoadjuvant radiation 57 prognostic variables 57 Refractory Hodgkin Lymphoma 57 lymph node dissection 57 ipsilateral breast 57 Trastuzumab 57 cytotoxic chemotherapy 57 HBsAg 57 adecatumumab 57 surgically resectable 57 advanced metastatic prostate 57 hematologic toxicity 57 untreated AML 57 cT3 prostate cancer 57 eribulin mesylate 57 grade squamous intraepithelial 57 ELACYT 57 GPNMB 57 sustained virologic response 57 cisplatin gemcitabine 57 NPM1 mutations 57 recurrent VTE 57 ABCB1 57 ® lenalidomide 57 refractory chronic lymphocytic 57 hormonal therapies 57 SLN biopsy 57 HBeAg 57 IFN α 57 resistant ovarian cancer 57 soft tissue sarcomas 57 erlotinib Tarceva 57 adenomatous polyps 57 thalidomide Thalomid 57 genotype 1a 57 mammographically 57 acute leukemias 57 Ophena TM 57 grade gliomas 57 evaluating Xcytrin 57 Velcade bortezomib 57 cetuximab Erbitux 57 ACR# responses 57 CTAP# Capsules 57 evaluable patients 57 EGFR mutant 57 cediranib 57 T2DM 57 Acute Myeloid Leukaemia AML 57 Vidaza ® 57 Diffuse Large B 57 pegylated interferon alpha 57 antiestrogen 57 pain palliation 57 SUVmax 57 Pralatrexate 57 HLA A2 57 seronegative 57 ERalpha 57 relapsed acute myelogenous 57 Immunohistochemical staining 57 response pCR 57 ARB telmisartan 57 relapsed refractory 57 FluCAM 57 polyp recurrence 57 F FDG PET 57 estrogen receptor 57 mCRPC 57 HBeAg seroconversion 57 PCNSL 57 osteosarcomas 57 rituximab refractory 57 EGFR TKIs 57 oral ridaforolimus 57 radical nephrectomy 57 AGTR1 57 doxorubicin HCl liposome injection 57 lactate dehydrogenase LDH 57 GW# [003] 57 carcinoid tumors 57 perioperatively 57 KRAS oncogene 57 nucleoside analogue 57 μmol L 57 myelofibrosis polycythemia vera 57 CsA 57 pancreatic NET 57 metastatic HER2 positive 57 axillary node dissection 57 MDA MB 57 antitumor effect 57 conventional DMARDs 57 Adjuvant Treatment 57 micafungin 57 Soft Tissue Sarcoma 57 paclitaxel eluting stents 57 EpCAM expression 57 Metastatic Breast Cancer 57 lobular cancer 57 diabetes mellitus DM 57 TroVax ® 57 taxane 57 hyperplasia BPH 57 sentinel nodes 57 baseline HbA1c 57 CC genotype 57 elevated transaminases 57 bladder ovarian 57 resected pancreatic cancer 57 mammographic density 57 letrozole Femara 57 BRCA2 mutation carriers 57 invasive ductal breast cancer 57 BRCA2 mutations 57 Median survival 57 Tarceva TM 57 gastric cancers 57 nodal metastases 57 axitinib 57 Xeloda ® 57 mutated BRAF gene 57 bleomycin 57 anaplastic 57 hepatitis C genotype 57 precursor lesions 57 ALT elevation 56 comparator arm 56 AGILECT R 56 lung carcinomas 56 KRAS mutation 56 BEACOPP 56 PD LID 56 factor receptor 56 diagnosed multiple myeloma 56 PCA3 scores 56 gemcitabine cisplatin 56 promoter methylation 56 advanced pancreatic neuroendocrine 56 Hormone receptor 56 free survival PFS 56 pancreatic prostate 56 preoperative PSA 56 Surgical resection 56 bilateral orchiectomy 56 tumor subtypes 56 complete cytogenetic 56 Metastatic colorectal cancer 56 antiretroviral naïve 56 Relapsed Refractory 56 antibody titer 56 GBM tumors 56 colorectal cancer liver metastases 56 Aflibercept 56 metastatic neuroendocrine tumors 56 Ceplene/IL-2 56 mapatumumab 56 genotypic resistance 56 metachronous 56 p# deficient 56 recurrent glioblastoma 56 undergo prostate biopsy 56 anthracyclines taxanes 56 Bortezomib 56 chronic HCV genotype 56 Pharmacokinetics PK 56 neoplasm 56 mildly symptomatic 56 estrogen progesterone 56 metastatic lymph nodes 56 HER2 neu 56 relapsed ALL 56 ovarian cancers 56 Natalizumab 56 mutational status 56 antiangiogenic agent 56 5 fluorouracil leucovorin 56 metastatic lesions 56 lung metastasis 56 neratinib 56 sleeve lobectomy 56 % CI #.#-#.# [007] 56 AVASTIN 56 androgen suppression 56 cetuximab Erbitux R 56 HER2/neu 56 thromboembolic events 56 RSR# efaproxiral 56 malignant ovarian 56 doxorubicin cyclophosphamide 56 colorectal gastric 56 cervical lymph nodes 56 BRAF V# mutation 56 lintuzumab 56 metastatic ovarian cancer 56 sipuleucel T 56 docetaxel Injection Concentrate 56 lobular involution 56 orchiectomy 56 parous women 56 pegylated liposomal doxorubicin PLD 56 peg interferon 56 cytoreductive nephrectomy 56 recurrent prostate cancer 56 p# mutation 56 trastuzumab Herceptin ® 56 Ishak fibrosis score 56 remission CR 56 abacavir lamivudine 56 plus prednisone 56 nonmelanoma skin cancers 56 advanced neoplasia 56 ER CHOP 56 HIV coinfected 56 MabCampath 56 NNRTI resistance 56 dose dexamethasone 56 activating mutations 56 TKIs 56 FUSILEV enhances 56 paclitaxel Taxol ® 56 EOquin TM phase 56 prednisone prednisolone 56 CDK4 56 VIDAZA 56 sustained virological response 56 malignant cancerous 56 chemopreventive agent 56 H. pylori eradication 56 hypercalcemia 56 tumor shrinkage 56 achieve sustained virologic 56 IIIA NSCLC 56 Gefitinib 56 mitoxantrone plus 56 HERmark 56 IFN beta 56 tirofiban 56 pmol L 56 beta estradiol 56 sulphonylureas 56 Subgroup analyzes 56 recurrent colorectal cancer 56 prospectively defined 56 follicular lymphoma FL 56 idarubicin 56 CTA# Injection 56 folinic acid 56 leukemia ALL 56 liposomal doxorubicin 56 Ovary removal 56 adenocarcinoma 56 lamivudine refractory patients 56 refractory ovarian cancer 56 lumbar spine BMD 56 Exemestane 56 colorectal adenoma 56 Campath alemtuzumab 56 Leukemias 56 sunitinib 56 nonfatal MI 56 neuroblastoma tumors 56 thienopyridine 56 durable remissions 56 Vandetanib 56 plus gemcitabine 56 hormone LHRH 56 recurrent malignant glioma 56 refractory metastatic 56 grade cervical dysplasia 56 Xelox 56 achieved sustained virological 56 hormonally responsive 56 FDG PET 56 Radical prostatectomy 56 hypogonadal 56 overexpress 56 axillary lymph node 56 paclitaxel 56 Camptosar ® irinotecan 56 hormone therapy estrogen 56 ToGA 56 peginterferon alfa 56 Accelerated Partial Breast Irradiation 56 immunomodulatory therapy 56 hepatocellular carcinoma 56 gemcitabine Gemzar ® 56 remission induction 56 EGFR TK 56 HBeAg positive patients 56 exemestane 56 chemotherapy regimens 56 metastatic lung cancer 56 radical prostatectomy RP 56 mg TID 56 external beam radiotherapy 56 Advanced Renal Cell 56 Ph + acute lymphoblastic 56 Pemetrexed 56 paclitaxel Taxol 56 monotherapy 56 immunohistochemical analysis 56 elacytarabine 56 Thalomid ® 56 Anthracycline 56 cyclophosphamide chemotherapy 56 TRAIL induced apoptosis 56 malignant ascites 56 thromboembolisms 56 refractory cutaneous T 56 catheter angiography 56 imatinib Gleevec ® 56 pancreatic ovarian 56 methotrexate monotherapy 56 glycoprotein IIb IIIa inhibitors 56 pg ml 56 epirubicin cyclophosphamide 56 refractory CTCL 56 Navelbine ® 56 tumor necrosis 56 NSCLC tumors 56 MetS 56 squamous cell histology 56 adverse cytogenetics 56 metastatic androgen independent 56 axillary node 56 BRIM3 56 Newly Diagnosed Multiple Myeloma 56 imatinib resistant 56 Panzem R NCD 56 hepatoma 56 Metastatic breast cancer 56 malignant growths 56 BRIM2 56 HBeAg positive 56 diagnosed glioblastoma multiforme 56 log# copies mL 56 non metastatic resectable 56 decitabine 56 urine cytology 56 mcg albinterferon alfa 2b 56 rs# [002] 56 p# Shc 56 octreotide LAR 56 Alkeran 56 targeting CD# 56 xenografts 56 HBeAg + 56 grade dysplasia 56 FOLFOX chemotherapy 56 prostate pancreatic 56 prostatic adenocarcinoma 56 mutant KRAS 56 HER2 positive breast cancer 56 deletion 5q 56 lenalidomide dexamethasone 56 STRIDE PD 55 Mitoxantrone 55 Gemzar gemcitabine 55 pelvic lymphadenectomy 55 x ULN 55 Gemzar ® 55 transitional cell carcinoma 55 smoldering multiple myeloma 55 erlotinib 55 specific antigen PSA 55 IV metastatic melanoma 55 saline placebo 55 relapsed refractory multiple myeloma 55 dose cytarabine 55 interleukin IL -# 55 Taxotere ® 55 CD#c 55 TAXUS Express Stent 55 metastatic relapsed 55 bevacizumab 55 Cristofanilli 55 potentially hepatotoxic 55 Pegylated Interferon 55 FASLODEX 55 asymptomatic metastatic